Panikcure provides an AI‑driven infrastructure for CNS drug development that delivers quantitative, multimodal neural biomarker readouts to objectively measure how a compound interacts with brain targets. By isolating true drug‑induced neural signals from placebo response, the platform predicts clinical significance and generates clear go/no‑go decisions that integrate directly into existing Phase I study arms without added operational burden. This enables early detection of failures and faster advancement of promising candidates.
Funding
Funding not disclosed
Founders
Product
Problem
Early-stage CNS drug programs lack objective, quantitative measures to determine whether a compound truly engages neural targets, leading to reliance on subjective clinical intuition and high risk of late-stage failure.
Solution
Panikcure offers an AI-driven platform that captures multimodal neural signals during Phase I trials and isolates drug‑induced activity from placebo effects. The system applies statistically grounded analyses to generate a reproducible neural biomarker readout that predicts clinical significance. By integrating directly into existing study designs without added operational burden, Panikcure provides a clear go/no‑go decision based on objective brain response rather than intuition. This early, evidence‑based decision point helps developers discontinue ineffective candidates sooner and allocate resources to promising therapies.
Target Audience
Primary customers are pharmaceutical companies and biotech firms developing central nervous system therapeutics that need early, objective validation of target engagement in Phase I clinical studies.
Features
- Multimodal neural signal acquisition (e.g., EEG, MEG, fMRI) combined with AI analytics to quantify brain response
- Statistical framework that translates neural activity into a biomarker linked to clinical outcomes
- Automated separation of true drug‑induced signals from placebo response for reliable go/no‑go signaling
- Seamless integration into existing Phase I trial workflows without modifying study design
- Reproducible decision output that replaces subjective clinical judgment with data‑driven evidence